BioNTech Entered into a Research Collaboration with Medigene to Boost T Cell Receptor Immunotherapies Against Cancer
Shots:
- Medigene to receive $29.37M up front & research funding & will be eligible to receive development, regulatory & commercial milestone along with tiered deferred option fees & royalties. BioNTech gets an exclusive option to acquire additional TCRs in Medigene’s discovery pipeline & get the license to Medigene’s PD1-41BB switch receptor & precision pairing technologies
- BioNTech will hold exclusive commercialization rights globally on all TCR therapies & will lead the global development of the product
- The collaboration will use BioNTech’s immunotherapy capabilities & Medigene’s TCR discovery platform to develop TCR immunotherapies for multiple solid tumor targets selected by BioNTech
Ref: Globe Newswire | Image: Bloomberg
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com